(Q35923949)

11 August 2017

1 reference

title

Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications (English)

1 reference

11 August 2017

1 reference

1 reference

1 reference

Robinson M

1

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

Alimentary Pharmacology & Therapeutics

11 August 2017

published in

1 reference

11 August 2017

volume

20 Suppl 6

1 reference

11 August 2017

page(s)

1-10

1 reference

Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Review article: current practice and future perspectives in the management of gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Importance of pH control in the management of GERD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Review article: acid suppression in the management of gastro-oesophageal reflux disease--an appraisal of treatment options in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Review article: Barrett's oesophagus, dysplasia and pharmacologic acid suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Review article: the control of gastric acid and Helicobacter pylori eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Helicobacter pylori infection. The importance of eradication in patients with gastric disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Review article: the pharmacology of rabeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Review article: Esomeprazole--enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

Review article: drug interactions with agents used to treat acid-related diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02160.X

10.1111/J.1365-2036.2004.02160.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference